Literature DB >> 23991981

The effect of abraxane on cell kinetic parameters of HeLa cells.

Nurcan Gurses1, Mehmet Topcul.   

Abstract

Abraxane (nab-paclitaxel) is a member of the group of nano chemotherapeutics. It is approved for metastatic breast cancer and non small cell lung cancer. Trials for several cancer types including gynecological cancers, head and neck, and prostatic cancer are being studied. In this study, the antiproliferative and apoptotic effect of abraxane was evaluated on HeLa cell line originated from human cervix carcinoma. Three different doses (D1=10 nM, D2=50 nM, D3=100 nM) were administered to HeLa cells for 24, 48 and 72 h. The 50 nM dose of abraxane decreased DNA synthesis from 4.62-0.08%, mitosis from 3.36-1.89% and increased apoptosis from 10.6-30% at 72 h. Additionally, tripolar metaphase plates were seen in mitosis preparations. In this study, abraxane effected cell kinetic parameters significantly. This results are consistent with other studies in the literature.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23991981     DOI: 10.7314/apjcp.2013.14.7.4229

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  1 in total

Review 1.  Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer.

Authors:  Dan Ai; Yan Guan; Xiu-Ju Liu; Chu-Feng Zhang; Peng Wang; Hong-Lu Liang; Qi-Sen Guo
Journal:  Onco Targets Ther       Date:  2016-09-16       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.